Last reviewed · How we verify
Adult growth hormone deficiency — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Sogroya | SOMAPACITAN | Novo Nordisk | Growth hormone receptor | 2020-01-01 | ||
| SOGROYA | SOMAPACITAN-BECO | NOVO NORDISK INC | Growth hormone receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- NOVO NORDISK INC · 1 drug in Adult growth hormone deficiency
- Novo Nordisk · 1 drug in Adult growth hormone deficiency
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Adult growth hormone deficiency:
- Adult growth hormone deficiency treatment updates — RSS
- Adult growth hormone deficiency treatment updates — Atom
- Adult growth hormone deficiency treatment updates — JSON
Cite this brief
Drug Landscape (2026). Adult growth hormone deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adult-growth-hormone-deficiency. Accessed 2026-06-10.
Related
- Adult growth hormone deficiency full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing